-- 獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師的觀點總結如下：我們將BLDR的12個月目標價從125美元下調至85美元，基於2027年13.1倍的市盈率，該倍數高於該股10年平均預期市盈率12.1倍，但考慮到市場週期性低谷，這一調整是合理的。我們將2026年調整後每股盈餘預期從6.69美元下調至4.10美元，並將2027年調整後每股盈餘預期從8.01美元下調至6.50美元。 BLDR公佈的2026年第一季調整後每股收益為0.27美元，低於市場預期的1.51美元（年減82%），也遠低於市場普遍預期的0.37美元。 BLDR第一季銷售額下降11%至32.9億美元（比市場預期高出1.3億美元），但毛利率下降220個基點至28.3%。 BLDR表示，目前預計2026年淨銷售額為146億至156億美元，調整後EBITDA為11億至15億美元，而先前的預期分別為148億至158億美元和13億至17億美元。管理層表示，公司將繼續專注於自身可控因素，包括服務客戶、拓展差異化增值解決方案組合以及利用技術加速成長並提升營運效率。我們認為，BLDR第一季的業績凸顯了該公司在疲軟的房地產市場中所面臨的挑戰。
Related Articles
Asia
Star Sports Medicine Soars 192% in Hong Kong Trading Debut
Star Sports Medicine's (HKG:1609) shares opened 192.4% above their initial public offering price in a stellar Hong Kong debut Tuesday morning.The China-based medical device company opened at HK$288 per share, well above the offer price of HK$98.50.
$HKG:1609
Asia
Impact Therapeutics Launches Up to HK$913 Million Hong Kong IPO
Impact Therapeutics (HKG:7630) launched its Hong Kong initial public offering on Tuesday, seeking to raise up to about HK$913 million from the deal.The China-based biotechnology company is offering 42 million shares at an indicative maximum price of HK$21.75 per share, according to a Hong Kong bourse filing.The offering comprises 4.2 million shares for Hong Kong investors and 37.8 million shares for international investors, subject to reallocation and the overallotment option.The offer price is expected to be determined by May 11, with allocation results due by May 12, ahead of the company's planned trading debut on May 13.Net proceeds will be used mainly to fund the clinical development, regulatory approval, and commercialization of its core product, senaparib, as well as support the development of key pipeline products.The funds will also be used for research and development of other pipeline assets, expansion of R&D platforms, and for working capital and general corporate purposes.Goldman Sachs (Asia) and China International Capital Corporation Hong Kong Securities are acting as joint sponsors.Goldman Sachs (Asia) and China International Capital Corporation Hong Kong Securities are serving as overall coordinators and are also acting as joint bookrunners and joint lead managers.CMB International Capital is acting as a joint global coordinator and joint lead manager, while Tiger Brokers (HK) Global is acting as a joint bookrunner and joint lead manager.
$HKG:7630
Asia
Market Chatter: SK Hynix Shares Gain 13% After US Tech Giants Signal No Slowdown in AI Spending
Shares of SK Hynix (KRX:000660) closed nearly 13% higher on Monday, ending trading at a new high of 1,447,000 won per share, after all four of the US tech giants indicated that spending on AI will not slow down, Reuters said in a same-day report.Total AI spending is estimated to surpass $700 billion in 2026, up from about $600 billion previously, as Microsoft and Meta announced larger-than-expected capital expenditure plans, which were partly led by higher memory chip prices, while maintaining confidence in their investments, the report said.In addition, Bank of Korea Senior Deputy Governor Ryoo Sang-dai said that the current chip market boom is likely to last longer as compared to past cycles, echoing similar outlooks from Samsung Electronics (KRX:005930) and SK Hynix during their earnings calls in April, it said.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
$KRX:000660$KRX:005930